Status:
COMPLETED
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled wi...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- type 2 diabetes mellitus;
- treated with stable sulfonylurea monotherapy or metformin + sulfonylurea for \>=12 weeks prior to screening;
- HbA1c \>=7.0% and \<=10% at screening;
- stable weight +/-5% for \>=12 weeks prior to screening.
Exclusion
- type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes;
- clinically significant diabetic complications;
- clinically symptomatic gastrointestinal disease;
- \>3 episodes of severe hypoglycemia within 6 months before screening.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
756 Patients enrolled
Trial Details
Trial ID
NCT00909597
Start Date
May 1 2009
End Date
November 1 2010
Last Update
November 2 2016
Active Locations (147)
Enter a location and click search to find clinical trials sorted by distance.
1
Buena Park, California, United States, 90620
2
Chino, California, United States, 91710
3
Los Angeles, California, United States, 90057
4
Rancho Cucamonga, California, United States, 91730